|L - Antineoplastic and Immunomodulating Agents|
This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
|L04 - Immunosuppressants|
Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.
|L04A - Immunosuppressants|
This group comprises immunosuppressants excl. corticosteroids.
The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.
|L04AA - Selective Immunosuppressants|
Antilymphocyte immunoglobulin from horse serum is classified in L04AA03.
Antithymocyte immunoglobulin from rabbit serum is classified in L04AA04.
Oral formulations of cladribine used in multiple sclerosis are classified in this group, while parenteral formulations for cancer are classified in L01BB.
The DDD for muromonam-CD3 is based on combination therapy in acute allograft rejection.
The DDDs for leflunomide, abatacept and tofacitinib are based on the treatment of rheumatoid arthritis.
The DDDs for natalizumab, fingolimod, teriflunomide and alemtuzumab are based on the treatment of multiple sclerosis.
The DDD for efalizumab is based on the treatment of psoriasis.
The DDD for eculizumab is based on the dose given in the maintenance phase.
The DDDs for alemtuzumab and cladribine are based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.
|L04AA23 - Natalizumab|
|10 mg||P|| |